We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome.
- Authors
Teachey, David T; Greiner, Robert; Seif, Alix; Attiyeh, Edward; Bleesing, Jack; Choi, John; Manno, Catherine; Rappaport, Eric; Schwabe, Dirk; Sheen, Cecilia; Sullivan, Kathleen E; Zhuang, Hongming; Wechsler, Daniel S; Grupp, Stephan A
- Abstract
We hypothesized that sirolimus, an mTOR inhibitor, may be effective in patients with autoimmune lymphoproliferative syndrome (ALPS) and treated patients who were intolerant to or failed other therapies. Four patients were treated for autoimmune cytopenias; all had a rapid complete or near complete response. Two patients were treated for autoimmune arthritis and colitis, demonstrating marked improvement. Three patients had complete resolution of lymphadenopathy and splenomegaly and all patients had a reduction in double negative T cells, a population hallmark of the disease. Based on these significant responses, we recommend that sirolimus be considered as second-line therapy for patients with steroid-refractory disease.
- Publication
British journal of haematology, 2009, Vol 145, Issue 1, p101
- ISSN
1365-2141
- Publication type
Journal Article
- DOI
10.1111/j.1365-2141.2009.07595.x